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Chronic graft-versus-host disease (cGVHD) is a severe complication
of allogeneic haematopoietic stem cell transplantation. There is a
growing understanding of cGVHD, and several effective
therapies for cGVHD have been reported. However, pancreatic
cGVHD is a potentially untapped study field. Our thoughtprovoking study using a mouse model of cGVHD suggested that
the pancreas could be impaired by cGVHD-induced
inflammation and fibrosis and that endoplasmic reticulum (ER)
stress was augmented in the pancreas affected by cGVHD. These
findings urged us to treat pancreatic cGVHD through reduction
of ER stress, and we used 4-phenylbutyric acid (PBA) as an ER
stress reducer. A series of experiments has indicated that PBA can
suppress cGVHD-elicited ER stress in the pancreas and
accordingly alleviate pancreatic cGVHD. Furthermore, we
focused on a correlation between epithelial to mesenchymal
transition (EMT) and fibrosis in the cGVHD-affected pancreas,
because EMT was conceivably implicated in various fibrosisassociated diseases. Our investigation has suggested that the
expression of EMT markers was increased in the cGVHDdisordered pancreas and that it could be reduced by PBA. Taken
together, we have provided a clue to elucidate the pathogenic
process of pancreatic cGVHD and created a potentially effective
treatment of this disease using the ER stress alleviator PBA.

Electronic supplementary material is available
online at https://dx.doi.org/10.6084/m9.figshare.
c.4247957.
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Chronic graft-versus-host disease (cGVHD) is an immunologically mediated complication and hampers
success in allogeneic haematopoietic stem cell transplantation (HSCT). In medical settings, cGVHD
typically occurs in allogeneic HSCT recipients six months or later after transplantation, and they can
suffer from multisystem disorders which resemble those induced by autoimmune diseases [1,2]. For
instance, dry eye, skin rashes, diarrhoea and respiratory failure are caused by cGVHD, and these
disabling symptoms can impact detrimentally on patients’ quality of life [1]. From a scientific point of
view, it is conceivable that cGVHD arises from minor histocompatibility differences between donorderived immune cells and recipient cells [1]. Although cGVHD has been studied intensively over a
long period of time, the exact mechanisms of cGVHD remain to be unravelled. However, there is
increasing elucidation of the pathogenic process of cGVHD. Most recently, several research groups
have used a mouse model of cGVHD and developed potentially efficacious methods to cure cGVHD
in various organs [3–7]. Despite the recent advancement of therapies for cGVHD, to the best of our
knowledge, no comprehensive biological investigation into pancreatic cGVHD has been reported thus
far. This fact urged us to gain more insights into cGVHD in the pancreas. In clinical practice, cGVHD
patients can be affected by diabetes, and it has been conceived to arise from corticosteroid therapies,
not from disorders in the pancreas [8,9]. Thus, we envisaged that it would be of great medical
importance to focus on the state of the pancreas in cGVHD sufferers.
Our recent work has demonstrated (i) that endoplasmic reticulum (ER) stress is augmented in organs
impaired by cGVHD, (ii) that the augmentation of ER stress is detrimentally associated with the
development of inflammation and fibrosis caused by cGVHD and (iii) that the attenuation of ER
stress by systemic injection of 4-phenylbutyric acid (PBA) could be a safe, reliable and robust strategy
to pave the way for the treatment of clinical cGVHD [10].
ER stress is conceived to be connected with chronic inflammation and age-related disorders [11,12].
The ER is a cellular organelle which maintains the proper functions of each cell. After the synthesis of
proteins in the ER, they are required to be folded into adequate forms, and the protein folding can be
achieved with the assistance of ER chaperones [13]. However, the essential functions of the ER can be
disturbed by the following phenomena: hypoxia, calcium ion depletion, oxidative injury and viral
infections [14,15]. Aberrant accumulation of unfolded and/or misfolded proteins causes ER stress, and
accordingly, the following three transmembrane proteins are released from glucose-regulated protein
78 (GRP78) to start the unfolded protein response (UPR): inositol requiring (IRE) 1a, PKR-like ER
kinase (PERK) and activating transcription factor 6a [13]. However, the prolonged and/or
unsuccessful UPR causes the activation of inflammatory and apoptotic pathways [13]. Hence, in the
case where the UPR is prolonged and/or unsuccessful, it results in the out-of-control expression and/
or activation of (i) the proinflammatory molecules transcription factor nuclear factor kappa-lightchain-enhancer of activated B cells (NF-kB) and thioredoxin interaction protein (TXNIP) and (ii) the
apoptotic protein C/EBP homologous protein (CHOP) [16 –21].
In this study using a mouse model of cGVHD, it was envisioned that the pancreas could be susceptible
to cGVHD-elicited inflammation and fibrosis and that the use of ER stress reducer PBA could be a
promising approach to cure pancreatic cGVHD. Herein, we report our novel endeavours to unravel the
pathogenic process of cGVHD in the pancreas and treat the potentially under-explored disease.
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2. Material and methods
Eight-week-old B10.D2 and BALB/c mice were purchased from Sankyo Laboratory, Inc. (Tokyo, Japan).
All the scientific experiments on mice were performed in accordance with the Animal Welfare Act at Keio
University School of Medicine. Our protocols for experiments on animals were approved by the animal
care and use committee at Keio University (Approval no. 09152). It should also be noted that no
fieldwork was conducted in this study.

2.1. Bone marrow transplantation
Bone marrow transplantation (BMT) was carried out to afford a murine model of cGVHD [22]. In the
case where the donors were B10.D2 mice and the recipients were BALB/c mice, it was allogeneic
BMT (allo-BMT) to produce a murine model of cGVHD. By contrast, BMT from BALB/c to BALB/c
mice was syngeneic BMT (syn-BMT), and therefore cGVHD did not occur in the transplant recipients.
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1. Introduction

2.2. Treatment of allogeneic bone marrow transplantation recipient mice with 4-phenylbutyric
acid

2.3. Histological analysis of the pancreas and immunohistochemistry for paraffin-embedded
tissue sections
Three or four weeks after BMT, the pancreas was collected from the transplant recipient mice. These
samples were subsequently fixed with 10% neutral-buffered formalin and embedded in paraffin. The
paraffin blocks were cut into 7 mm-thick sections, and then stained with (i) haematoxylin and eosin
(HE), (ii) Mallory’s trichrome [23,24] and (iii) antibodies used in this study. For the
immunohistochemical assays, paraffin was removed in the first instance. To stain the sections with a
CD45 antibody (30-F11, BD Pharmingen, San Jose, CA, USA) or an E-cadherin antibody (24e10, Cell
Signaling Technology, Danvers, MA, USA), they were immersed in the antigen retrieval solution
(Target Retrieval Solution; Dako, Glostrup, Denmark) and then boiled with a microwave oven for
10 min, and the reactions between the antigens in tissue sections and the primary antibodies were
conducted at 48C overnight. The sections were then treated with fluorophore-labelled secondary
antibodies with 40 ,6-diamidino-2-phenylindole (DAPI) for nuclear staining at room temperature for
45 min and mounted with an anti-fading mounting medium (Fluorescent Mounting Medium; Dako).
Fluorescence images were taken with an LSM confocal microscope (Carl Zeiss, Jena, Germany). As for
the counting of CD45þ cells, five areas of each tissue section were randomly photographed at 200
magnification, and the number of CD45þ cells in the individual images was subsequently determined.
With respect to secondary antibodies, goat anti-rat IgG (H þ L) secondary antibody, Alexa Fluor 568
conjugate (Molecular Probes) and goat anti-rabbit IgG (H þ L) secondary antibody, Alexa Fluor 488
conjugate (Molecular Probes) were used to detect CD45. Rat IgG2b, k (eB149/10H5, eBioscience, San
Diego, CA, USA) and rabbit IgG (Cell Signaling Technology, Danvers, MA, USA) were used as
isotype controls for CD45 and E-cadherin, respectively.

2.4. Immunohistochemistry for frozen tissue sections
Three or four weeks after BMT, the pancreas was collected from the transplant recipient mice. These
samples were subsequently fixed with 10% neutral-buffered formalin and embedded in Tissue-Tek
OCT Compound (Sakura Finetek, Torrance, CA, USA) to produce formalin-fixed frozen blocks. The
frozen blocks were then cut into 7 mm-thick sections and preserved at 2808C until they were used.
In order to carry out multiple staining for CHOP (H-43, Santa Cruz Biotechnology, Santa Cruz, CA,
USA) and CD68 (FA-11, AbD Serotec, Kidlington, UK), the formalin-fixed frozen sections were defrosted
at 378C, fixed with acetone at room temperature for 20 min, washed with PBS (3  3 min) and heated up
in the antigen retrieval solution (HistoVT One; Nakalai Tesque, Kyoto, Japan) at 708C for 20 min with a
water bath.
After the activity of the target antigens was recovered, the sections were blocked with 10% normal
goat serum, and the reactions between the antigens in tissue sections and the primary antibodies were
conducted at 48C overnight. The sections were then treated with fluorophore-labelled secondary
antibodies with DAPI for nuclear staining at room temperature for 45 min and mounted with an antifading mounting medium (Fluorescent Mounting Medium; Dako). Fluorescence images were taken
with an LSM confocal microscope (Carl Zeiss, Jena, Germany). In this immunohistochemical
examination, the following secondary antibodies were used: goat anti-rabbit IgG (H þ L) secondary
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We conducted BMT as described above, and the allo-BMT recipient mice were divided into two groups.
One group was treated with PBA (10 mg kg21) (Aldrich, St Louis, MO, USA), and the other was given
the solvent-vehicle phosphate buffer saline (PBS; pH 7.4) by intraperitoneal injection. We administered
the inhibitor or the solvent-vehicle to the allo-BMT recipients once per day from Day 10 to Day 27
after BMT. They were sacrificed Day 28 after BMT.

3
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The recipient mice without cGVHD served as syngeneic control subjects. The recipients were irradiated
with 700 cGy prior to the BMT, and the lethal irradiation was performed using a Gammacel 137 Cs
source (Hitachi Medico, Ltd, Tokyo, Japan). A suspension containing 1  106 bone marrow cells and
2  106 spleen cells from the donors was administered to each of the recipient mice via tail vein.
The donor cells were suspended in RPMI 1640 (Life Technologies Japan Ltd, Tokyo, Japan).

2.5. Electron microscopy

2.6. Immunoblotting analysis
The tissues of interest were placed in Eppendorf tubes, and pre-cooled RIPA buffer was added to the
tubes. The tissues were then homogenized using an electric homogenizer. After the samples were on
ice for 1 h, they were centrifuged at 15 000 r.p.m. at 48C for 5 min. The supernatants were
subsequently collected in fresh tubes on ice and used as cell lysates. An equal amount of 5 Laemmli
buffer was added to each cell lysate, followed by protein denaturation at 1008C for 5 min. Equal
amounts of protein from each sample were loaded into the wells of SDS-PAGE gels and then resolved.
The proteins were transferred from the gels to membranes at 15 V for 20 min. The membranes were
blocked with 5% skim milk or 5% BSA in 1  TBST (a mixture of Tris-buffered saline and tween 20) at
room temperature for 1 h. The membranes were then incubated with primary antibodies at 48C
overnight. The primary antibodies were diluted 1000 times with 5% skim milk or 5% BSA in 1  TBST.
After the primary antibody incubation, the membranes were washed with 1  TBST (3  10 min),
subjected to secondary antibody at room temperature for 1 h and then washed with 1  TBST (3 
10 min) and 1  TBS (2  10 min). The proteins of interest were visualized using either of the following
two methods. (i) Colorimetric detection of the target proteins was conducted using BCIP/NBT
substrate (Promega, WI, USA). (ii) Signals were developed with an enhanced chemoluminescence
(ECL) detection reagent (GE Healthcare, Littlecalfont, UK), and the target proteins were subsequently
visualized with a LAS 4000 mini chemiluminescence imaging system (Fujifilm/GE Healthcare).
Densitometric analysis of the obtained protein bands was conducted with the use of the image
processing software ImageJ. The primary antibodies used in this experiment were as follows: GRP78
(Abcam, Cambridge, UK), phospho-PERK (Thr980, Cell Signaling Technology), PERK (C33E10, Cell
Signaling Technology), phosphor-IRE1a (Thermo Fisher Scientific, Waltham, MA, USA), IRE1a (14C10
Cell Signaling Technology), phosphor-eIF2a (119A11, Cell Signaling Technology), eIF2a (Cell Signaling
Technology), CHOP (9C8, Thermo Fisher Scientific), TXNIP (D5F3E, Cell Signaling Technology), NF-kB
(Abcam), IL-6 (Abcam), connective tissue growth factor (CTGF) (Abcam), E-cadherin (24e10, Cell
Signaling Technology), a-smooth muscle actin (SMA) (1A4, Abcam), Snail (C15D3, Cell Signaling
Technology) and b-actin (AC-15, Abcam). With regard to the secondary antibodies, (i) when the protein
bands were visualized by developing a colour, either an AP-conjugated anti-mouse IgG antibody
(Promega) or an AP-conjugated anti-rabbit IgG antibody (Promega) was used, and (ii) either an HRPconjugated anti-mouse antibody (Thermo Fisher Scientific) or an HRP-conjugated anti-rabbit antibody
(Thermo Fisher Scientific) was required to detect the target proteins by ECL.

2.7. Measurement of blood glucose levels
Blood glucose levels were measured by the Japanese company Sanritsu Zelkova (Kanagawa, Japan).
The measurement was conducted with the use of a kit (27E1X80166000006, LSI Medience, Japan).
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Transmission electron microscopic analysis was performed according to standard protocols. Tissues were
collected from the murine pancreas, immediately fixed with 2.5% glutaraldehyde in 0.1 M phosphate
buffer ( pH 7.4) at 48C for 4 h and washed three times with 0.1 M phosphate buffer. The samples were
subsequently fixed again with 2% osmium tetroxide, dehydrated in a graded series of ethanol and
100% propylene oxide, and embedded in epoxy resin. One micrometre sections were made from the
processed tissues and then stained with methylene blue. The thick sections were observed with a
microscope to find parts which were suitable for preparation of ultrathin sections. The obtained
sections were placed on mesh grids, stained with uranylacetate and lead citrate and examined with an
electron microscope (1230 EXII; JEOL, Tokyo, Japan). All electron micrographs were acquired with a
bio scan camera (Gatan bio scan camera model 792, Tokyo, Japan).

4

rsos.royalsocietypublishing.org

antibody, Alexa Fluor 488 conjugate (Molecular Probes, Eugene, OR, USA) goat anti-rat IgG (H þ L)
secondary antibody, Alexa Fluor 568 conjugate (Molecular Probes) and goat anti-American hamster
IgG (H þ L) secondary antibody, Alexa Fluor 568 conjugate (Molecular Probes). With regard to
isotype controls, rat IgG2a (54447, R&D Systems, Minneapolis, MN, USA) and rabbit IgG (Cell
Signaling Technology) were used for CD68 and CHOP, respectively.

2.8. Statistical analysis

5

Statistical significance was determined with the use of unpaired Student’s t-test. Differences are
considered significant in the case of p , 0.05. The acquired data are presented as means + s.d.
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3. Results
3.1. Histological analysis of the pancreas affected by chronic graft-versus-host disease

3.2. Elevation of endoplasmic reticulum stress markers in the pancreas disordered by chronic
graft-versus-host disease
The novel histological elucidation of pancreatic cGVHD urged us to investigate a detrimental link
between ER stress and cGVHD by measuring the following ER stress indicators: GRP78, CHOP,
p-PERK, p-eIF2a and p-IRE1a. As judged by immunoblot analysis, the ER stress markers in the
cGVHD-affected pancreas were expressed at higher level than its syngeneic control partner (GRP78:
p ¼ 1.3  1025, CHOP: p ¼ 2.0  1024, p-PERK: p ¼ 6.0  1026, p-eIF2a: p ¼ 2.4  1024, p-IRE1a: p ¼
0.0012) (figure 2a,b; electronic supplementary material, figure S8a–e). As a consequence of the
activation of ER stress signalling pathways, the following two inflammation-related molecules were
elevated and/or activated in the cGVHD-disordered pancreas in contrast to its syngeneic control
counterpart: NF-kB and TXNIP (NF-kB: p ¼ 3.9  1027, TXNIP: p ¼ 4.9  1026) (figure 2a,b; electronic
supplementary material, figure S8f,g). These results are indicative of the fact that ER stress was
elevated in the pancreas disordered by cGVHD.

3.3. Augmentation of epithelial to mesenchymal transition markers in the pancreas disordered
by chronic graft-versus-host disease
Our examination indicated that the pancreas was vulnerable to fibrosis elicited by cGVHD, and a
survey of literature revealed that epithelial to mesenchymal transition (EMT) was involved in
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In the first instance, we conducted histological investigation into the pancreas. As indicated by HE
and Mallory’s staining, tissues around ducts in the pancreas collected from allo-BMT recipients
were excessively inflamed in association with mononuclear cell infiltration and fibrotic in concert
with extracellular matrix accumulation (figure 1a,b; electronic supplementary material, figures S1
and S2). Conversely, when mice underwent syn-BMT, their pancreas seemed to be virtually
normal (figure 1a,b; electronic supplementary material, figures S1 and S2). This finding indicated
that pancreatic exocrine failure could be induced by cGVHD. Immunostaining for the generic
leucocyte marker CD45 also revealed that abnormal immune cell migration was observed in the
cGVHD-disordered pancreas by contrast with its syngeneic control equivalent ( p ¼ 0.00038)
(figure 1c,d; electronic supplementary material, figure S3). In addition, the size of pancreatic islets
was greatly reduced in the cGVHD-affected mice in contrast to that in their syngeneic control
counterparts (figure 1e; electronic supplementary material, figure S4). Presumably owing to the
dysfunctional exocrine and endocrine glands [25 – 27], the blood glucose levels in the cGVHDaffected mice were substantially greater than those in the syngeneic control subjects ( p ¼ 0.000029)
(figure 1f ). The degree of inflammation and fibrosis was determined by immunoblot assays for
the inflammatory markers IL-6 and CTGF [28,29]. Our data indicated that these two markers were
expressed at higher level in the cGVHD-affected pancreas compared with its syngeneic control
partner (IL-6: p ¼ 6.9  1025, CTGF: p ¼ 1.2  1024) (electronic supplementary material, figures S5
and S6). Furthermore, electron micrographic analysis was carried out to examine the state of the
pancreas more closely. The electron micrographs of cGVHD-affected pancreatic epithelia suggested
(i) that the ER was abnormally expanded and distorted owing to aberrant accumulation of
proteins, (ii) that the walls of blood vessels in the stroma were extremely thin in association with
multiple fenestrations, (iii) that the cristae of mitochondria in acinar cells were distorted and
damaged and (iv) that the mitochondria were expanded (figure 1g; electronic supplementary
material, figure S7). As shown by these findings, the pancreas is presumably prone to cGVHD-triggered
inflammation and fibrosis.
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Figure 1. Histological assays for the pancreas disordered by cGVHD. (a) HE pictures of the cGVHD-affected pancreas and its syngeneic control
partner. The images were taken at 200 magnification, and the scale bar is 200 mm. Severely inflamed portions are shown with blue
asterisks. The enlarged version of each picture is shown in electronic supplementary material, figure S1. (b) Mallory’s staining for the
cGVHD-disordered pancreas and its syngeneic control equivalent. The photographs were taken at 200 magnification, and the scale
bar is 200 mm. Aberrantly fibrotic areas are shown with white asterisks. The enlarged version of each picture is shown in electronic
supplementary material, figure S2. (c) Immunostaining for the generic leucocyte marker CD45 in the cGVHD-impaired pancreas
and its syngeneic control counterpart. Cell membranes and nuclei are stained red and blue, respectively. The images were taken at
200 magnification, and the scale bar is 20 mm. The enlarged version of each picture is shown in electronic supplementary material,
figure S3. (d) The density of CD45 positive cells in the pancreas from syn-BMT recipient mice (blue) and cGVHD-affected ones (red).
The data are presented as means + s.d., control: n ¼ 3, cGVHD: n ¼ 3. (e) HE pictures of pancreatic islets in syn-BMT recipient mice
and cGVHD-disordered ones. A pancreatic islet is shown with a black arrow. The images were taken at 400 magnification, and the
scale bar is 100 mm. The enlarged version of each picture is shown in electronic supplementary material, figure S4. ( f ) Blood glucose
levels in syn-BMT recipient mice and cGVHD-disordered ones. The data are presented as means + s.d., control: n ¼ 5, cGVHD: n ¼ 5.
(g) Electron micrographs of cGVHD-affected pancreas and its syngeneic control counterpart. Cap, capillary; M, mitochondrion. The
pictures of stroma in the pancreas (i,iv) were at 2000 magnification, and the scale bar is 5 mm. Asterisks are placed where the ER is
expanded due to the accumulation of proteins, and cell debris is shown with rectangles. The photographs of blood vessels in the
pancreas (ii,v) were at 5000 magnification, and the scale bar is 500 nm. Damaged blood vessels are displayed with an ellipse. The
photographs of mitochondria in the pancreas (iii,vi) were at 15 000 magnification, and the scale bar is 500 nm. The enlarged
version of each picture is shown in electronic supplementary material, figure S7.
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Figure 2. ER stress markers in the cGVHD-affected pancreas. (a) Immunoblot analysis of ER stress indicators and the associated
inflammatory molecules was carried out (lane 1: syngeneic control subject, lane 2: cGVHD-affected pancreas). Cropped blots are
displayed, and the corresponding full-length gels are shown in electronic supplementary material, figure S8. (b) The
corresponding quantitative analysis of the protein bands was conducted. cGVHD-affected pancreas (red) and its syngeneic
control counterpart (blue). Results are representative of two independently performed experiments with similar results. The
data are presented as means + s.d., control: n ¼ 5, cGVHD: n ¼ 5.
various fibrosis-associated disorders [30 – 34]. Hence, we hypothesized that it would be the case with
pancreatic cGVHD. In order to investigate our hypothesis, immunostaining and immunoblot analysis
were conducted to examine the expression levels of EMT markers. As shown by immunohistochemical
and immunoblot assays, the expression of the EMT indicator E-cadherin in the cGVHD-affected
pancreas was decreased in contrast to that in its syngeneic control equivalent ( p ¼ 0.0016)
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Figure 3. EMT markers in the cGVHD-affected pancreas. (a) Immunostaining for E-cadherin in cGVHD-affected pancreas and its
syngeneic control counterpart. E-cadherin and cell nuclei are stained green and blue, respectively. The fluorescence images were
at 200 magnification, and the scale bar is 20 mm. (b) Immunoblot analysis of E-cadherin and a-SMA was carried out
(lane1: syngeneic control subject, lane 2: cGVHD-affected pancreas). Cropped blots are displayed, and the corresponding fulllength gels are shown in electronic supplementary material, figure S9. (c) The corresponding quantitative analysis of the
protein bands was conducted. cGVHD-affected pancreas (red) and its syngeneic control counterpart (blue). Results are
representative of two independently performed experiments with similar results. The data are presented as means + s.d.,
control: n ¼ 5, cGVHD: n ¼ 5.
(figure 3a – c; electronic supplementary material, figure S9a). Moreover, immunoblot analysis indicated
that the EMT markers a-SMA and Snail in the cGVHD-affected pancreas were expressed at higher
level than those in their syngeneic control partners (a-SMA: p ¼ 0.0084, Snail: p ¼ 0.022) (figure 3b,c;
electronic supplementary material, figure S9b,c). These data suggested that EMT was linked to
cGVHD-elicited fibrosis in the pancreas.

3.5. Histological observations of chronic graft-versus-host disease target organs
In order to investigate the extent of inflammation and fibrosis in the PBA- and vehicle-treated pancreas
from allo-BMT recipients, HE and Mallory staining was conducted. The HE and Mallory pictures
suggested that areas around pancreatic ducts in PBA-medicated pancreas were less inflamed and
fibrotic compared with its vehicle-medicated partner (figure 5a,b; electronic supplementary material,
figures S11 and S12). In addition, immunohistochemical analysis showed (i) that the number of
immune cells in the PBA-injected pancreas was vastly lower than that in its vehicle-injected equivalent
( p ¼ 0.005) (figure 5c,d; electronic supplementary material, figure S13) and (ii) that macrophages
expressing CHOP were observed in the vehicle-treated pancreas in contrast to its PBA-treated
counterpart (electronic supplementary material, figure S14). Furthermore, pancreatic islets in the PBAtreated allo-BMT recipient mice were larger than those in their vehicle-treated counterparts (figure 5e;
electronic supplementary material, figure S15). Presumably, as a result of the protection of exocrine
and endocrine glands, the blood glucose levels in the PBA-medicated allo-BMT recipients were
normal in contrast to those in their vehicle-medicated equivalents ( p ¼ 2.2  1027) (figure 5f ).
Immunoblot analysis of IL-6 and CTGF also indicated that systemic injection of PBA suppressed
cGVHD-elicited inflammation and fibrosis in contrast to the solvent-vehicle (IL-6: p ¼ 6.9  1027,
CTGF: p ¼ 1.6  1028) (electronic supplementary material, figures S16 and S17). Moreover, judging
from electron micrographic analysis, pancreatic epithelia treated with PBA had almost normal
structure of ER, blood vessels and mitochondria (figure 5g; electronic supplementary material, figure S18).
By contrast, in vehicle-treated pancreatic epithelia, the ER appeared to be expanded due to abnormal
accumulation of proteins, the wall of a capillary was extremely thin, and mitochondria seemed to be
damaged and lose their cristae (figure 5g; electronic supplementary material, figure S18).

3.6. Repression of chronic graft-versus-host disease-elicited epithelial to mesenchymal
transition in pancreas by 4-phenylbutyric acid
We subsequently investigated whether PBA could suppress EMT, which was conceivably associated with
excessive fibrosis in the pancreas affected by cGVHD. Immunohistochemistry and immunoblot analysis
revealed that E-cadherin was retained in the PBA-treated pancreas in contrast to its vehicle-treated
counterpart ( p ¼ 7.4  1024) (figure 6a–c; electronic supplementary material, figure S19a). In addition,
the protein levels of a-SMA and Snail in the PBA-medicated pancreas seemed to be normal, whereas
a-SMA and Snail were overexpressed in its vehicle-medicated partner (a-SMA: p ¼ 0.0019 and Snail:
p ¼ 0.0082) (figure 6b,c; electronic supplementary material, figure S19b,c).

4. Discussion
Allogeneic HSCT recipients are subjected to risk of cGVHD, which can affect multiple organs and cause a
wide range of disabling symptoms. Although cGVHD in many organs has been investigated over recent
decades, pancreatic cGVHD has been virtually unstudied. Thus, we were prompted to examine the state
of the pancreas affected by cGVHD using a well-established mouse model. As demonstrated by our
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Once we discovered the detrimental association between ER stress and pancreatic cGVHD, our ensuing
attempt was to cure cGVHD in the pancreas by reducing ER stress. As described in the section Material
and methods, we treated allo-BMT recipient mice with PBA or the solvent-vehicle. As judged by
immunoblot analysis, the pancreas collected from the PBA-treated mice displayed the lower protein
levels of GRP78, CHOP, p-PERK, p-eIF2a and p-IRE1a compared with that collected from their
vehicle-treated counterparts (GRP78: p ¼ 3.0  1028, CHOP: p ¼ 5.7  1027, p-PERK: p ¼ 4.4  1027, peIF2a: p ¼ 1.3  1025, p-IRE1a: p ¼ 5.4  1024) (figure 4a,b; electronic supplementary material, figure
S10a–e). As a consequence, the proinflammatory molecules NF-kB and TXNIP, which are in the
downstream of ER stress signalling pathways, were repressed in the pancreas treated with PBA in
comparison to its vehicle-treated equivalent (NF-kB: p ¼ 1.2  1025, TXNIP: p ¼ 1.9 2 1024)
(figure 4a,b; electronic supplementary material, figure S10f,g).
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3.4. Treatment of pancreatic chronic graft-versus-host disease through reduction of endoplasmic
reticulum stress

(a)

1

2

10

rsos.royalsocietypublishing.org

GRP78
CHOP
P-PERK
PERK
P-eIF2a

R. Soc. open sci. 5: 181067

eIF2a
P-IRE1a
IRE1a
NF-kB p65
TXNIP
b-actin

P-PERK

P-eIF2a

P-IRE1a

NF-kB

TXNIP

4.4 × 10–7

1.3 × 10–5

5.4 × 10–4

1.2 × 10–4

2.0 × 10–4

P
ve BA
hic
le

P
ve BA
hic
le

P
ve BA
hic
le

CHOP

p = 3.0 × 10–8 5.7 × 10–7

P
ve BA
hic
le

GRP78

(b)

P
ve BA
hic
le

lane 1: PBA-treated pancreas
lane 2: vehicle-treated pancreas

1.0

relative intensity

0.8

0.6

0.4

0.2

P
ve BA
hic
le

P
ve BA
hic
le

0

Figure 4. The ability of PBA to lower cGVHD-induced ER stress. (a) Immunoblot analysis of ER stress indicators and the associated
inflammatory molecules was carried out (lane1: PBA-treated pancreas, lane 2: vehicle-treated pancreas). Cropped blots are displayed,
and the corresponding full-length gels are shown in electronic supplementary material, figure S10. (b) The corresponding
quantitative analysis of the protein bands was conducted. PBA-medicated pancreas (blue) and its vehicle-medicated counterpart
(red). Results are representative of two independently performed experiments with similar results. The data are presented as
means + s.d., control: n ¼ 6, cGVHD: n ¼ 6.
previous investigation, the pathogenic processes of lacrimal gland cGVHD in this murine model were
similar to those in patients with cGVHD [3,35 –37]. As with the human lacrimal glands affected by
cGVHD, abnormal inflammation and fibrosis were observed in their murine counterparts. In addition,
previous reports demonstrated that inflammation and fibrosis were induced systemically in this
mouse model [3,36,38]. Therefore, we examined the development of pancreatic cGVHD using this
murine model.
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Figure 5. Effectiveness of PBA for cGVHD shown by histological investigation. (a) HE pictures of the PBA-injected pancreas and its
vehicle-injected partner. The images were taken at 200 magnification, and the scale bar is 200 mm. Severely inflamed portions
are shown with blue asterisks. The enlarged version of each picture is shown in electronic supplementary material, figure S11.
(b) Mallory’s staining for the pancreas treated with PBA and that treated with the solvent-vehicle. The photographs were taken
at 200 magnification, and the scale bar is 200 mm. Aberrantly fibrotic areas are shown with white asterisks. The enlarged
version of each picture is shown in electronic supplementary material, figure S12. (c) Immunostaining for the generic leucocyte
marker CD45 in the PBA-medicated pancreas and its vehicle-medicated equivalent. Cell membranes and nuclei are stained red
and blue, respectively. The images were taken at 200 magnification, and the scale bar is 20 mm. The enlarged version of
each picture is shown in electronic supplementary material, figure S13. (d) The density of CD45 positive cells in the PBAtreated pancreas (blue) and its vehicle-treated counterpart (red). The data are presented as means + s.d., PBA: n ¼ 3, vehicle:
n ¼ 3. (e) HE pictures of pancreatic islets in PBA-medicated recipient mice and vehicle-medicated ones. A pancreatic islet is
shown with a black arrow. The images were taken at 400 magnification, and the scale bar is 100 mm. The enlarged version
of each picture is shown in electronic supplementary material, figure S15. ( f ) Blood glucose levels in PBA-treated mice and
vehicle-treated ones. The data are presented as means + s.d., PBA: n ¼ 6, vehicle: n ¼ 6. (g) Electron micrographs of the
PBA-injected pancreas and its vehicle-injected counterpart. Cap, capillary; M, mitochondrion. The pictures of stroma in the
pancreas (i,iv) were at 2000 magnification, and the scale bar is 5 mm. Asterisks are placed where the ER is expanded due
to the accumulation of proteins, and cell debris is shown with rectangles. The photographs of blood vessels in the pancreas
(ii,v) were at 5000 magnification, and the scale bar is 500 nm. Damaged blood vessels are displayed with an ellipse. The
photographs of mitochondria in the pancreas (iii,vi) were at 15 000 magnification, and the scale bar is 500 nm. The
enlarged version of each picture is shown in electronic supplementary material, figure S18.
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Figure 6. EMT markers in the cGVHD-affected pancreas. (a) Immunostaining for E-cadherin in the PBA-treated pancreas and its
vehicle-treated counterpart. E-cadherin and cell nuclei are stained green and blue, respectively. The fluorescence images were at
200 magnification, and the scale bar is 20 mm. (b) Immunoblot analysis of E-cadherin and a-SMA was carried out (lane 1:
PBA-injected pancreas, lane 2: vehicle-injected pancreas). Cropped blots are displayed, and the corresponding full-length gels are
shown in electronic supplementary material, figure S19. (c) The corresponding quantitative analysis of the protein bands was
conducted. PBA-medicated pancreas (blue) and its vehicle-medicated counterpart (red). Results are representative of two
independently performed experiments with similar results. The data are presented as means + s.d., PBA: n ¼ 6, vehicle: n ¼ 6.
Our histological investigation revealed that the pancreas in allo-BMT recipient mice was aberrantly
inflamed and fibrotic and that the pancreas was vulnerable to cGVHD. In particular, severe
inflammation and fibrosis around pancreatic ducts were induced, and pancreatic islets were shrunk.
Previous reports indicated that exocrine failure as well as endocrine failure in the pancreas could result
in diabetes [25–27]. Hence, it is conceivable that the exocrine and endocrine failure in cGVHD-affected
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committee at Keio University (Approval no. 09152).
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pancreas resulted in diabetes-like symptoms and thereby the blood glucose levels in mice with cGVHD
were augmented. Moreover, as confirmed by immunoblot investigation, the expression of the
inflammatory marker IL-6 [28] and the fibrotic indicator CTGF [29] was higher in the cGVHD-affected
pancreas compared with its syngeneic control partner. IL-6 is conceivably involved in the differentiation
of naive T cells into regulatory T cells or proinflammatory T cells [39,40]. Hence, IL-6 has captured
interest from many researchers working on GVHD. Also, because CTGF is reported to be overexpressed
in a wide range of fibrosis-associated diseases, it can indicate the degree of fibrosis in a reliable manner
[41]. Furthermore, our electron microscopic examination into pancreas disordered by cGVHD suggested
that (i) the ER in the cGVHD-affected epithelia was expanded owing to the accumulation of proteins,
(ii) the blood vessels were seriously demolished and (iii) mitochondria in the epithelia were severely
damaged. Our survey of previous articles revealed that mitochondria could be destroyed as a result of
increased ER stress. Hence, the expanded ER and the damaged mitochondria were indicative of
escalation of ER stress.
Accordingly, with the novel findings above, we next investigate pancreatic cGVHD more closely. Our
recent report indicates that the elevation of ER stress in cGVHD-disordered organs is associated with
abnormal inflammation and fibrosis [10]. Thus, we envisaged that it was also applicable to the
pancreas. Our data suggested (i) that ER stress markers were expressed at higher level in the pancreas
affected by cGVHD compared with its syngeneic control counterpart and (ii) that accordingly the
cGVHD-impaired pancreas displayed the higher expression of the inflammation-associated molecules
NF-kB and TXNIP. The elevation of TXNIP prompted us to carry out a survey of literature, and
previous articles demonstrated that TXNIP was detrimentally correlated with EMT and that EMT was
related to fibrosis elicited by cGVHD [42,43]. In this study, we focused on the following EMT
markers: E-cadherin, a-SMA and Snail. Literature precedent suggests (i) that EMT can be promoted
by loss of E-cadherin, which is expressed in epithelial cells, (ii) that the increased expression of
a-SMA in vascular smooth muscle cells and myoepithelial cells is correlated with EMT and (iii) that
Snail is presumed to suppress the expression of E-cadherin [30,44]. Our investigation into the EMT
indicators suggested that EMT occurred in the cGVHD-affected pancreas and contributed to the
development of cGVHD-triggered fibrosis in a deleterious manner.
With these outcomes, we subsequently attempted to treat pancreatic cGVHD. As reported in our
recent article, the ER stress reducer PBA can be an effective medication to treat cGVHD in various
organs. Thus, we attempted to combat pancreatic cGVHD by treating allo-BMT recipients with PBA.
Our data suggested the ability of PBA to reduce cGVHD-induced ER stress and the corresponding
proinflammatory molecules in the pancreas. As a consequence, judging from the results of histological
and immunohistochemical examination, cGVHD-caused inflammation and fibrosis were reduced in
the PBA-treated pancreas by contrast with its vehicle-treated partner. Especially, PBA treatment
subdued inflammation and fibrosis around pancreatic ducts, prevented pancreatic islets from
shrinking and retained normal blood glucose levels in all-BMT recipient mice. Electron microscopic
assays also underpinned our claim by showing that PBA kept the ER, blood vessels and mitochondria
in pancreatic epithelia virtually intact.
Literature precedent suggests that PBA shows the capacity to restrain EMT, which results in fibrosis
[45]. This report and our encouraging outcomes prompted us to more meticulously investigate how PBA
protected the pancreas from fibrosis induced by cGVHD. Our immunohistochemical and immunoblot
assays for EMT makers in the PBA- and vehicle-injected pancreas suggested that PBA could suppress
EMT induced by cGVHD. As stated above, TXNIP is reported to be implicated in EMT. Thus, it is
conceivable that PBA suppressed the ER stress-induced expression of TXNIP, with the result that EMT
caused by cGVHD was subdued.
In clinical settings, some cGVHD patients suffer from diabetes. Historically, it has been presumed to
arise from the conventional steroid treatment [8,9]. However, our basic study has suggested that diabetes
in allogeneic HSCT recipients could result from cGVHD-induced inflammation and fibrosis in the
pancreas and that the ER stress attenuator PBA has the potential to prevent the new onset of diabetes.
Overall, our animal study has indicated that the pancreas can be disordered by cGVHD-elicited
inflammation and fibrosis and that systemic injection of PBA can prevent and/or mitigate pancreatic
cGVHD. Hence, our novel investigation into pancreatic cGVHD may change the current insights into
diabetes occurring in allogeneic HSCT recipients and facilitate the treatment of cGVHD in medical settings.

Date accessibility. The datasets supporting this article have been uploaded as part of the electronic supplementary
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